Enveric Biosciences Inc vs Taskus Inc — how do they compare? Enveric Biosciences Inc trades at $1.32 (market cap $5.32M), while Taskus Inc trades at $5.95 (market cap $547.18M). The key difference: Taskus Inc is far larger — about 102.9× Enveric Biosciences Inc's market cap. Which is the better fit depends on your goals.
| ENVB | TASK | |
|---|---|---|
Market Cap | $5.32M | $547.18M |
Sector | Health | Technology |
52-Week High | $17.40 | $18.21 |
52-Week Low | $1.28 | $4.57 |
Enterprise Value | $408.82K | $942.88M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TaskUs (TASK) trades at $5.80, up 3.2% on the day, with technical indicators signaling a bullish trend. The stock appears fundamentally undervalued with a P/E of 5.29 and P/S of 0.46, supported by strong profitability metrics including a 37.05% gross margin and 26.52% ROE. Recent quarterly earnings have mostly beaten expectations, and the company announced a new CFO appointment in June 2026, highlighting ongoing corporate development.
The outlook is positive given the stock's significant discount to analyst consensus price targets near $9.50, representing over 60% upside potential. Key risks include potential earnings volatility, as seen in a recent Q1 2026 miss, and execution risks in a competitive outsourcing sector. The bullish analyst consensus and strong cash generation from operations support a constructive view.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →